Alain H Rook MD

Professor of Dermatology, University Pennsylvania

University of Pennsylvania, 3400 Civic Center Blvd.1-Perelman SouthPhiladelphia, PA 19104
Phone+1 215-662-7610
Fax+1 215-615-4966

Dr. Rook is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rook's full profile Already have an account?

Summary

Dr. Alain Rook is a dermatologist based in Philadelphia, PA, with expertise in cutaneous T-cell lymphoma and skin malignancies. He completed his medical education at the University of Michigan Medical School and pursued further training in Immunology, Dermatology, Internal Medicine, and Nephrology. Dr. Rook has contributed to the field through various publications on topics like CAR T-cell therapies and the treatment of mycosis fungoides and Sézary syndrome. He has also been involved in clinical trials regarding cytokine therapies and Toll-like receptor agonists. He has received several honors, including recognition by Philadelphia Magazine and Castle Connolly as one of America's top doctors and a lifetime achievement award from the International Society for Cutaneous Lymphomas and the Outstanding Clinical Specialist Award from the University of Pennsylvania Health System.

Education & Training

University of Pennsylvania Health SystemResidency, Dermatology, 1986 - 1989
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1984 - 1986
McGill UniversityFellowship, Nephrology, 1977 - 1979
McGill University Residency, Internal Medicine, 1975 - 1977
University of Michigan Medical SchoolClass of 1975

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 1986 - 2026
MD State Medical License 1981 - 1993
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017

Clinical Trials

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden.
Colin J Thomas, Caroline S Myers, Jina Chung, Daniel Landsburg, Sunita D Nasta
Blood Neoplasia. 2026-08-01
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.
Shujing Liu, Alain H Rook, Alexander C Huang, Amit Maity, Zhiyuan Qin
Cancer Immunology Research. 2026-06-11
Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.
Jonathan A Baron, Leah Cohen, Monica Chelius, Ian Messing, John Mallon
Clinical Lymphoma, Myeloma & Leukemia. 2026-05-01

Journal Articles

Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome
Paul L Haun, Sara S Samimi, Alain H Rook, Ellen J Kim, JAMA Dermatology
Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome
Ellen J Kim, Carmela Vittorio, Paul L Haun, Sara S Samimi, Rachael A Clark, Alain H Rook, JAMA Dermatology

Lectures

Management Issues in Cutaneous Lymphoma
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Other

Clinical presentation, pathologic features, and diagnosis of S??zary syndrome
Rook AH, Olsen EA
http://www.uptodate.com/contents/clinical-presentation-pathologic-features-and-diagnosis-of-sezary-s
UpToDate, Wolters Kluwer Health - 2013-02-05

Press Mentions

'Chromosomal Chaos:' Complex Array of Mutations Found in Rare, Aggressive LeukemiaOctober 7th, 2015
Topical Gel Appears Safe, Effective in CTCLAugust 7th, 2015
Triple Therapy Regime Puts Patients with Leukemic Form of Cutaneous Lymphoma in RemissionAugust 19th, 2011

Grant Support

Toll Receptor Ligand Therapy Of Cutaneous T-Cell LymphomaNational Cancer Institute2008–2011
Immunotherapy Of Cutaneous T-Cell Lymphoma With Interleukin-12National Cancer Institute2007–2008
Dendritic Cell Defects In Cutaneous T-Cell LymphomaNational Cancer Institute2003–2007
Immunotherapy Of Cutaneous T-Cell Lymphoma WNational Cancer Institute2004–2006
Recombinant Interleukin-12 For Cutaneous T-Cell LymphomaNational Cancer Institute2001–2006